2017 Autumn Conference includes Joint Day with ECNP
31 August – 02 September, 2017 // Le Meridien Etoile, Paris, FR
Distinguished Poster Award Recipients: |
||
Effect of High within Subject Variance at Research Sites on Placebo Response and Drug Placebo Separation in Acute Schizophrenia Trials – A Post Hoc Analysis (Kott)
Replication of a Statistical Method to Reduce Pseudospecificity and Enhance Understanding of Score Changes Among PANSS Factors (Mahableshwarkar) |
||
All Poster PDFs and Abstracts are available at the end of the second day. |
||
31 August 2017 |
||
Welcome Reception | ||
1 September 2017
|
||
Welcome from the Presidents | S Marder![]() C Arango ![]() ![]() |
|
Beyond Efficacy: Hard Outcomes in Treatment Studies | Chairs: N Schooler G Goodwin |
|
Introduction | G Goodwin![]() ![]() |
|
Within-subject comparison as a tool to explore effectiveness in register studies | M Landén![]() ![]() |
|
Relapse prevention studies: What happens after drop out? | S Leucht![]() ![]() |
|
Industry Perspective: Risk characterization utilizing external data sources: A methodological consideration for clinical trials with high subject drop-out | J Geier![]() ![]() |
|
Regulatory Comment/Panel Audience Discussion | M Tome![]() Speakers ![]() |
|
Clinician Reported Outcomes in Multinational CNS Trials: Practical Guidance on Translation and Cultural Adaptation | Chairs: A Kalali E Vieta |
|
Introduction and background | A Kalali![]() |
|
The impact of language and culture on implementing multinational clinical trials | M Vance![]() ![]() |
|
Cultural learnings implementing multinational clinical trials | E Vieta![]() ![]() |
|
Guidance document – overview and highlights | E Pappadopulos![]() ![]() |
|
Panel and audience discussion | Speakers![]() |
|
Drug Development for Negative Symptoms in Schizophrenia: What Have We Learned? What Can We Do Better? | Chairs: D Umbricht C Arango |
|
Welcome and introduction | D Umbricht![]() |
|
Negative symptoms: Prevalence, specificity, course and other characteristics | M Weiser![]() ![]() |
|
Preclinical models of negative symptoms and their implications for clinical trials | M Kas![]() ![]() |
|
Negative symptoms: Clinical assessments, biomarkers and the role of reward processing | J Gold![]() ![]() |
|
Lessons learned in recent trials in negative symptoms | D Umbricht![]() ![]() |
|
Conclusion and next steps | J Lieberman![]() ![]() |
|
Panel discussion/Regulatory Comment | Moderator: J Lieberman ![]() |
|
Concluding remarks | C Arango |
|
Joint meeting adjournment | S Marder C Arango ![]() |
|
ISCTM Poster Session | Poster PDFs and Abstracts | |
2 September 2017 |
||
Behavioral and Psychiatric Symptoms in Dementia (BPSD): A Way Forward? | Chairs: L Ereshefsky L Pani |
|
Background, brief overview and session’s purpose | L Ereshefsky L Pani |
|
Segment 1- Agitation in Alzheimer’s Disease | ||
Lessons Learned – Part One – Agitation in Alzheimer’s Disease – Progress in Trials Designs | B Creese![]() ![]() |
|
Lessons Learned – Part Two – Agitation in Alzheimer’s Disease – Developing New Treatments | P Rosenberg![]() ![]() |
|
Comments from Industry Perspective | S Dube![]() ![]() |
|
Regulatory Viewpoints – Agitation in AD | V Mantua![]() ![]() T Farchione ![]() ![]() |
|
Panel – Audience discussion – Agitation in AD | Facilitators: J Rasmussen J Bell Agitation Panel ![]() |
|
Segment 2 – Apathy in Alzheimer’s Disease | ||
Why focus on apathy? Diagnosis, symptoms assessment, methodology framework | D Miller![]() ![]() |
|
Neuro-circuitry and implications for drug development: ADMET trials, and study designs for treatment of apathy | K Lanctot![]() ![]() |
|
Quantifiable assessment of motivational deficits and apathy in dementia – and beyond | S Pollentier![]() ![]() |
|
Treatment of apathy in psychiatry and neurodegenerative disorders: Are positive valence systems of reward shared in common? Early drug development implications | L Ereshefsky![]() ![]() |
|
Concluding Discussant | Discussant: L Pani ![]() ![]() |
|
Regulatory Viewpoints/Panel – Audience discussion – Apathy in AD | Facilitators: L Ereshefsky S Pollentier Panel: T Farchione V Mantua ![]() Apathy speakers ![]() |
|
Meeting Adjourns | S Marder |